Mylan: Court Denies Injunction Against Generic Version Of Copaxone

(RTTNews) - Mylan Inc. (MYL) announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone pending the Supreme Court's decision on Teva's appeal.

Mylan CEO Heather Bresch said: "We look forward to introducing the first generic Copaxone treatment for multiple sclerosis patients in the U.S. at market formation. Mylan remains eligible to receive approval from the U.S. Food and Drug Administration on May 25, 2014."

This is the second time that the Chief Justice has denied Teva's request for such an injunction, Mylan noted.